Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Predictors of 30-day Readmission in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective, Cross-sectional Database Study.

Guzman AK, Zhang M, Kwatra SG, Kaffenberger BH.

J Am Acad Dermatol. 2019 Sep 19. pii: S0190-9622(19)32754-9. doi: 10.1016/j.jaad.2019.09.017. [Epub ahead of print]

PMID:
31542405
2.

Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States.

Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI.

J Am Acad Dermatol. 2017 May;76(5):811-817.e4. doi: 10.1016/j.jaad.2016.12.024. Epub 2017 Mar 9.

3.

A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.

Antoon JW, Goldman JL, Shah SS, Lee B.

J Allergy Clin Immunol Pract. 2019 Jan;7(1):244-250.e1. doi: 10.1016/j.jaip.2018.05.024. Epub 2018 May 30.

PMID:
29859332
4.

Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults.

Hsu DY, Brieva J, Silverberg NB, Silverberg JI.

J Invest Dermatol. 2016 Jul;136(7):1387-1397. doi: 10.1016/j.jid.2016.03.023. Epub 2016 Mar 30.

5.
6.

Stevens-Johnson syndrome/toxic epidermal necrolysis and erythema multiforme drug-related hospitalisations in a national administrative database.

Sousa-Pinto B, Ara├║jo L, Freitas A, Correia O, Delgado L.

Clin Transl Allergy. 2018 Jan 22;8:2. doi: 10.1186/s13601-017-0188-1. eCollection 2018.

7.

Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study.

Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB.

Am J Clin Dermatol. 2012 Feb 1;13(1):49-54. doi: 10.2165/11593240-000000000-00000.

PMID:
22145749
8.

Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.

Nguyen KD, Tran TN, Nguyen MT, Nguyen HA, Nguyen HA Jr, Vu DH, Nguyen VD, Bagheri H.

J Clin Pharm Ther. 2019 Feb;44(1):69-77. doi: 10.1111/jcpt.12754. Epub 2018 Aug 20.

PMID:
30129156
9.

Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Antoon JW, Goldman JL, Lee B, Schwartz A.

Pediatr Dermatol. 2018 Mar;35(2):182-187. doi: 10.1111/pde.13383. Epub 2018 Jan 9.

PMID:
29315761
10.

Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.

Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Musiek A, Ortega-Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG.

JAMA Dermatol. 2019 Apr 1;155(4):448-454. doi: 10.1001/jamadermatol.2018.5605. Erratum in: JAMA Dermatol. 2019 Jul 31;:.

PMID:
30840032
11.

Validation of Stevens-Johnson syndrome or toxic epidermal necrolysis diagnoses in the Clinical Practice Research Datalink.

Frey N, Bircher A, Bodmer M, Jick SS, Meier CR, Spoendlin J.

Pharmacoepidemiol Drug Saf. 2017 Apr;26(4):429-436. doi: 10.1002/pds.4124. Epub 2016 Nov 20.

PMID:
27868282
12.

Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database.

Abe J, Umetsu R, Mataki K, Kato Y, Ueda N, Nakayama Y, Hane Y, Matsui T, Hatahira H, Sasaoka S, Motooka Y, Hara H, Kato Z, Kinosada Y, Inagaki N, Nakamura M.

J Pharm Health Care Sci. 2016 Jun 21;2:14. doi: 10.1186/s40780-016-0048-5. eCollection 2016.

13.

Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea.

Yang MS, Lee JY, Kim J, Kim GW, Kim BK, Kim JY, Park HW, Cho SH, Min KU, Kang HR.

PLoS One. 2016 Nov 11;11(11):e0165933. doi: 10.1371/journal.pone.0165933. eCollection 2016.

14.

Corticosteroids in Stevens-Johnson Syndrome/toxic epidermal necrolysis: current evidence and implications for future research.

Law EH, Leung M.

Ann Pharmacother. 2015 Mar;49(3):335-42. doi: 10.1177/1060028014560012. Epub 2014 Nov 18. Review.

PMID:
25406459
15.

Epidemiology of ophthalmologic disease associated with erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis in hospitalized children in the United States.

Moreau JF, Watson RS, Hartman ME, Linde-Zwirble WT, Ferris LK.

Pediatr Dermatol. 2014 Mar-Apr;31(2):163-8. doi: 10.1111/pde.12158. Epub 2013 May 16.

16.

Early Readmission to Hospital in Cancer Patients with Malignant Pleural Effusions: Analysis of the Nationwide Readmissions Database.

Mitchell MA, Dhaliwal I, Mulpuru S, Amjadi K, Chee A.

Chest. 2019 Sep 19. pii: S0012-3692(19)33872-3. doi: 10.1016/j.chest.2019.09.007. [Epub ahead of print]

PMID:
31542449
17.

Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?

Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC.

Arch Dermatol. 2000 Mar;136(3):323-7.

PMID:
10724193
18.
19.

Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T.

Clin Rev Allergy Immunol. 2018 Feb;54(1):147-176. doi: 10.1007/s12016-017-8654-z. Review.

PMID:
29188475
20.

Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study.

Chow LLW, Shih KC, Chan JCY, Lai JSM, Ng ALK.

BMC Ophthalmol. 2017 May 12;17(1):65. doi: 10.1186/s12886-017-0464-9.

Supplemental Content

Support Center